vida: extract claims from 2026-05-12-fda-glp1-telehealth-warning-letters-screening-gap

- Source: inbox/queue/2026-05-12-fda-glp1-telehealth-warning-letters-screening-gap.md
- Domain: health
- Claims: 3, Entities: 5
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/algorithmic-telehealth-assessments-cannot-detect-complex-eating-disorder-presentations.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: "DePaul JHLI analysis identifies diagnostic gap: algorithmic assessments miss eating disorder subtypes that present in larger bodies or without obvious purging behaviors"
+confidence: experimental
+source: DePaul JHLI analysis April 2026, STAT News
+created: 2026-05-12
+title: Algorithmic telehealth assessments structurally cannot identify complex eating disorder presentations because atypical anorexia and non-purging bulimia require clinical specialist judgment that online questionnaires lack
+agent: vida
+sourced_from: health/2026-05-12-fda-glp1-telehealth-warning-letters-screening-gap.md
+scope: functional
+sourcer: DePaul JHLI
+supports: ["glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population"]
+related: ["clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+---
+
+# Algorithmic telehealth assessments structurally cannot identify complex eating disorder presentations because atypical anorexia and non-purging bulimia require clinical specialist judgment that online questionnaires lack
+
+DePaul Journal of Health Law and Innovation analysis (April 2026) argues that telehealth's algorithmic assessments cannot capture the psychological complexity needed to identify eating disorder risk. Specific diagnostic gap: atypical anorexia nervosa (presenting in larger body) or non-purging bulimia nervosa may be misdiagnosed as binge eating disorder. These presentations require clinical specialist judgment because they lack the visible markers (low BMI, purging behaviors) that structured questionnaires can detect. The mechanism is architectural: online assessments use standardized questions optimized for high-volume processing, but complex eating disorder presentations require contextual clinical judgment about psychological relationship to food, body image distortion, and compensatory behaviors that don't fit questionnaire categories. This creates a systematic screening failure for the exact population most likely to seek GLP-1s through telehealth: individuals in larger bodies with undiagnosed restrictive or compensatory eating patterns. The clinical risk: GLP-1s' delayed gastric emptying can trigger or worsen purging behaviors, and rapid appetite suppression can trigger or worsen restrictive behaviors—but these risks are invisible to algorithmic assessment.

domains/health/glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population.md

@@ -24,3 +24,10 @@ Dr. Kim Dennis identifies atypical anorexia as a specific high-risk population f
 **Source:** NPR Health, Feb 2026, clinical expert interviews
 
 Clinicians identify atypical anorexics as 'at high risk of being harmed' because they 'restrict food but maintain normal weight' making the condition invisible to doctors. Given GLP-1s are prescribed primarily for weight management, the typical candidate appearance overlaps with atypical AN presentation, creating a systematic detection failure. Nearly 10% of Americans meet clinical eating disorder criteria at some point, suggesting substantial overlap with GLP-1 candidate population.
+
+
+## Extending Evidence
+
+**Source:** DePaul JHLI April 2026, STAT News
+
+DePaul JHLI analysis (April 2026) adds mechanism: atypical anorexia nervosa (presenting in larger body) or non-purging bulimia nervosa may be misdiagnosed as binge eating disorder in algorithmic telehealth assessments. The diagnostic gap is architectural: online questionnaires cannot capture psychological complexity needed to identify these presentations.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -123,3 +123,10 @@ Review recommends 'monthly check-ins with validated depression/suicidality tools
 **Source:** NPR Health, Feb 2026, interviews with Robyn Pashby (psychologist) and Samantha DeCaro (clinician)
 
 NPR reporting confirms that 'most patients receive NO evaluation for eating disorders before GLP-1 prescription' and that drugs are 'easy to obtain online, with little screening.' Psychologist Robyn Pashby notes the screening gap exists despite identified risk populations. This provides journalistic confirmation of the structural screening gap documented in clinical literature.
+
+
+## Extending Evidence
+
+**Source:** ANAD guidance, STAT News March 2026
+
+ANAD's epistemic honesty adds evidence dimension: the professional society governing eating disorder standards explicitly states 'we simply do not know if these medications will improve, worsen, or have no impact on eating disorder behaviors.' This means prescribers are operating without professional society-grounded guidance, not just without regulatory mandates. The screening gap is both structural (no mandatory protocol) and epistemic (acknowledged evidence uncertainty by the authoritative professional body).

domains/health/glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway.md

@@ -10,7 +10,7 @@ agent: vida
 sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md
 scope: causal
 sourcer: ANAD
-related: ["glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+related: ["glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-induced-gi-side-effects-reinforce-existing-purging-cycles-but-no-clinical-evidence-supports-de-novo-eating-disorder-induction", "glp1-eating-disorder-risk-doubles-with-prior-mental-health-history"]
 ---
 
 # GLP-1 GI side effects trigger purging behaviors in vulnerable populations creating direct pharmacological harm pathway not just psychological reinforcement
@@ -30,3 +30,10 @@ ANAD states: 'Delayed gastric emptying can trigger or worsen purging behaviors,
 **Source:** PMC12694361 systematic review
 
 Systematic review refines mechanism: 'Gastrointestinal symptoms such as nausea and vomiting may complicate treatment, particularly in patients with purging behaviours, where these side effects could inadvertently reinforce or exacerbate existing cycles' — critically qualifies as 'existing cycles' not de novo induction. Requires pre-existing behavioral vulnerability markers: high perfectionism, obsessive-compulsive traits, elevated baseline emotional eating, mixed binge-purge patterns, weight suppression history.
+
+
+## Supporting Evidence
+
+**Source:** STAT News March 2026
+
+STAT News reports clinical risks: delayed gastric emptying can trigger or worsen purging behaviors, and rapid appetite suppression can trigger or worsen restrictive behaviors. Additionally, GLP-1 overdose poison control calls tripled, indicating misuse pattern (though not ED development specifically).

domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-ps
 scope: structural
 sourcer: MDPI Nutrients
 supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
-related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
+related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification"]
 ---
 
 # Pre-treatment eating disorder screening is recommended by clinical reviews but not required by any professional guideline or regulatory body despite 4-7x elevated pharmacovigilance risk
@@ -52,3 +52,10 @@ The AgRP silencing mechanism strengthens the case for mandatory (not just recomm
 **Source:** PMC12694361 systematic review
 
 Systematic review establishes specific screening protocol components: SCOFF questionnaire administration, recent ED history review, assessment for compensatory behaviors, weight-suppression history evaluation. Also identifies treatment red flags: rapid weight loss, dizziness/syncope, escalating restriction, purging or laxative use. Positioned as clinical governance recommendation within 'multidisciplinary care' framework.
+
+
+## Supporting Evidence
+
+**Source:** FDA warning letters March 2026, STAT News
+
+FDA warning letters (70+ issued through March 2026) target marketing claims but not prescribing practices, confirming that no regulatory enforcement mechanism exists for eating disorder screening. ANAD's recommended protocol (physician + therapist + dietitian all versed in both GLP-1s and EDs) remains guidance, not requirement.

domains/health/glp1-telehealth-prescribing-scales-without-eating-disorder-screening-infrastructure.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: The regulatory structure separates marketing oversight (FDA warning letters) from clinical practice standards (no mandatory screening protocol), enabling volume scaling without safety infrastructure
+confidence: experimental
+source: STAT News, FDA warning letters March 2026, ANAD guidance
+created: 2026-05-12
+title: GLP-1 telehealth prescribing scales without mandatory eating disorder screening because FDA regulates marketing claims but not prescribing criteria, leaving systematic risk assessment gaps
+agent: vida
+sourced_from: health/2026-05-12-fda-glp1-telehealth-warning-letters-screening-gap.md
+scope: structural
+sourcer: STAT News
+supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
+related: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification", "who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+---
+
+# GLP-1 telehealth prescribing scales without mandatory eating disorder screening because FDA regulates marketing claims but not prescribing criteria, leaving systematic risk assessment gaps
+
+FDA issued 70+ warning letters to GLP-1 telehealth companies for misleading marketing claims (FDA-approval claims, manufacturing claims), but these enforcement actions target marketing, not prescribing practices. No mandatory protocol exists to screen for eating disorders prior to GLP-1 prescribing. ANAD's guidance explicitly states 'we simply do not know if these medications will improve, worsen, or have no impact on eating disorder behaviors' and recommends pre-prescribing evaluation by physician + therapist + dietitian all versed in both GLP-1s and eating disorders. Actual telehealth practice: online assessment reviewed by licensed clinician, no eating disorder specialist required. The regulatory gap is structural: FDA authority covers product marketing and manufacturing claims, but clinical practice standards fall to professional societies (which issue guidance, not mandates) and state medical boards (which lack GLP-1-specific prescribing requirements). This enables telehealth platforms to scale prescribing volume at software speed—thousands of prescriptions per month per platform—without the clinical safeguard infrastructure the condition requires. The 30+ million potential user base faces no systematic eating disorder risk assessment despite ANAD's acknowledged evidence uncertainty.

domains/health/glp1-telehealth-warning-letters-target-concentrated-four-group-network.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: "Network structure analysis reveals regulatory leverage point: Beluga Health, OpenLoop, MD Integrations, and Telegra collectively support 30%+ of warned telehealth platforms"
+confidence: experimental
+source: STAT News investigation March 2026
+created: 2026-05-12
+title: FDA GLP-1 telehealth warning letters target a concentrated network where 30+ percent of warned firms affiliate with just four medical groups, making regulatory action on four organizations potentially market-transforming
+agent: vida
+sourced_from: health/2026-05-12-fda-glp1-telehealth-warning-letters-screening-gap.md
+scope: structural
+sourcer: STAT News
+related: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
+---
+
+# FDA GLP-1 telehealth warning letters target a concentrated network where 30+ percent of warned firms affiliate with just four medical groups, making regulatory action on four organizations potentially market-transforming
+
+STAT News investigation reveals that at least 30% of the 70+ telehealth firms receiving FDA warning letters maintain public affiliations with just 4 nationwide medical groups: Beluga Health, OpenLoop, MD Integrations, and Telegra. This is an interconnected network structure, not isolated bad actors. The business model separates marketing from prescribing: telehealth marketers make misleading claims (FDA-approval, manufacturing quality), while affiliated medical groups hold clinical responsibility for prescriptions. The concentration creates regulatory leverage: FDA warning letters are targeting a relatively concentrated network, not a diffuse regulatory problem. Regulatory action on these 4 organizations—whether through enforcement escalation, state medical board action, or federal prescribing standards—could significantly change the market structure. The network architecture also explains why marketing violations are so widespread: the separation of marketing (telehealth platform) from prescribing (affiliated medical group) creates accountability gaps where neither entity takes full responsibility for the patient journey from ad exposure to prescription.

entities/health/beluga-health.md

@@ -0,0 +1,29 @@
+---
+type: entity
+entity_type: company
+name: Beluga Health
+domain: health
+status: active
+founded: [unknown]
+headquarters: [unknown]
+funding: [unknown]
+key_people: []
+tags: [telehealth, medical-groups, GLP-1, prescribing-infrastructure]
+---
+
+# Beluga Health
+
+## Overview
+Beluga Health is one of four nationwide medical groups providing prescribing infrastructure for GLP-1 telehealth platforms. STAT News investigation (March 2026) identified Beluga Health as part of a concentrated network supporting at least 30% of telehealth firms that received FDA warning letters for misleading GLP-1 marketing.
+
+## Business Model
+Provides affiliated clinician services for telehealth platforms. The business model separates marketing (telehealth platform) from prescribing (medical group), creating accountability gaps where neither entity takes full responsibility for the patient journey.
+
+## Regulatory Context
+FDA warning letters (March 2026) targeted telehealth marketing firms, not the affiliated medical groups directly. However, the concentrated network structure (4 groups supporting 30%+ of warned firms) creates regulatory leverage point.
+
+## Timeline
+- **2026-03-12** — Identified by STAT News as one of four medical groups affiliated with 30%+ of FDA-warned GLP-1 telehealth firms
+
+## Sources
+- STAT News investigation, March 12, 2026

entities/health/depaul-jhli.md

@@ -0,0 +1,23 @@
+---
+type: entity
+entity_type: research_program
+name: DePaul Journal of Health Law and Innovation
+domain: health
+status: active
+parent_org: DePaul University College of Law
+tags: [health-law, digital-health, telehealth, regulatory-analysis]
+---
+
+# DePaul Journal of Health Law and Innovation (JHLI)
+
+## Overview
+DePaul Journal of Health Law and Innovation is a health law and innovation research institute at DePaul University College of Law. Focuses on regulatory analysis of emerging health technologies.
+
+## Key Research
+April 2026 analysis on GLP-1 telehealth prescribing identified that algorithmic assessments cannot capture the psychological complexity needed to identify eating disorder risk. Specific finding: atypical anorexia nervosa (presenting in larger body) or non-purging bulimia nervosa may be misdiagnosed as binge eating disorder in online questionnaire-based assessments.
+
+## Timeline
+- **2026-04** — Published analysis arguing telehealth algorithmic assessments structurally cannot detect complex eating disorder presentations requiring clinical specialist judgment
+
+## Sources
+- STAT News, March 12, 2026 (citing DePaul JHLI April 2026 analysis)

entities/health/md-integrations.md

@@ -0,0 +1,29 @@
+---
+type: entity
+entity_type: company
+name: MD Integrations
+domain: health
+status: active
+founded: [unknown]
+headquarters: [unknown]
+funding: [unknown]
+key_people: []
+tags: [telehealth, medical-groups, GLP-1, prescribing-infrastructure]
+---
+
+# MD Integrations
+
+## Overview
+MD Integrations is one of four nationwide medical groups providing prescribing infrastructure for GLP-1 telehealth platforms. STAT News investigation (March 2026) identified MD Integrations as part of a concentrated network supporting at least 30% of telehealth firms that received FDA warning letters for misleading GLP-1 marketing.
+
+## Business Model
+Provides affiliated clinician services for telehealth platforms. The business model separates marketing (telehealth platform) from prescribing (medical group), creating accountability gaps where neither entity takes full responsibility for the patient journey.
+
+## Regulatory Context
+FDA warning letters (March 2026) targeted telehealth marketing firms, not the affiliated medical groups directly. However, the concentrated network structure (4 groups supporting 30%+ of warned firms) creates regulatory leverage point.
+
+## Timeline
+- **2026-03-12** — Identified by STAT News as one of four medical groups affiliated with 30%+ of FDA-warned GLP-1 telehealth firms
+
+## Sources
+- STAT News investigation, March 12, 2026

entities/health/openloop.md

@@ -0,0 +1,29 @@
+---
+type: entity
+entity_type: company
+name: OpenLoop
+domain: health
+status: active
+founded: [unknown]
+headquarters: [unknown]
+funding: [unknown]
+key_people: []
+tags: [telehealth, medical-groups, GLP-1, prescribing-infrastructure]
+---
+
+# OpenLoop
+
+## Overview
+OpenLoop is one of four nationwide medical groups providing prescribing infrastructure for GLP-1 telehealth platforms. STAT News investigation (March 2026) identified OpenLoop as part of a concentrated network supporting at least 30% of telehealth firms that received FDA warning letters for misleading GLP-1 marketing.
+
+## Business Model
+Provides affiliated clinician services for telehealth platforms. The business model separates marketing (telehealth platform) from prescribing (medical group), creating accountability gaps where neither entity takes full responsibility for the patient journey.
+
+## Regulatory Context
+FDA warning letters (March 2026) targeted telehealth marketing firms, not the affiliated medical groups directly. However, the concentrated network structure (4 groups supporting 30%+ of warned firms) creates regulatory leverage point.
+
+## Timeline
+- **2026-03-12** — Identified by STAT News as one of four medical groups affiliated with 30%+ of FDA-warned GLP-1 telehealth firms
+
+## Sources
+- STAT News investigation, March 12, 2026

entities/health/telegra.md

@@ -0,0 +1,29 @@
+---
+type: entity
+entity_type: company
+name: Telegra
+domain: health
+status: active
+founded: [unknown]
+headquarters: [unknown]
+funding: [unknown]
+key_people: []
+tags: [telehealth, medical-groups, GLP-1, prescribing-infrastructure]
+---
+
+# Telegra
+
+## Overview
+Telegra is one of four nationwide medical groups providing prescribing infrastructure for GLP-1 telehealth platforms. STAT News investigation (March 2026) identified Telegra as part of a concentrated network supporting at least 30% of telehealth firms that received FDA warning letters for misleading GLP-1 marketing.
+
+## Business Model
+Provides affiliated clinician services for telehealth platforms. The business model separates marketing (telehealth platform) from prescribing (medical group), creating accountability gaps where neither entity takes full responsibility for the patient journey.
+
+## Regulatory Context
+FDA warning letters (March 2026) targeted telehealth marketing firms, not the affiliated medical groups directly. However, the concentrated network structure (4 groups supporting 30%+ of warned firms) creates regulatory leverage point.
+
+## Timeline
+- **2026-03-12** — Identified by STAT News as one of four medical groups affiliated with 30%+ of FDA-warned GLP-1 telehealth firms
+
+## Sources
+- STAT News investigation, March 12, 2026

inbox/archive/health/2026-05-12-fda-glp1-telehealth-warning-letters-screening-gap.md

@@ -7,10 +7,13 @@ date: 2026-03-12
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-12
 priority: medium
 tags: [GLP-1, telehealth, FDA, warning-letters, eating-disorders, screening, compounded-semaglutide, prescribing, governance]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content